Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 10, keine Gesamtzahl für „substrates“
Suchtreffer
Begriffe & Kennungen
Jinarc · 4.5 · 8 Transporter substrates P-glycoprotein substrates: In-vitro studies indicate that tolvaptan is a substrate an
Eintrag öffnenJinarc · 4.5 · CYP3A substrates In healthy subjects, tolvaptan, a CYP3A substrate, had no effect on the plasma concentrations
Eintrag öffnenJoenja · 4.5 · OAT3 substrates Leniolisib is an OAT3 inhibitor and may increase systemic exposure to OAT3 substrates (e.g., a
Eintrag öffnenJoenja · 4.5 · OATP1B1, OATP1B3, and BCRP substrates When co-administered, leniolisib increased rosuvastatin exposure 2-fold.
Eintrag öffnenJoenja · 4.5 · UDP-glucuronosyltransferase (UGT) 1A1 substrates In vitro, leniolisib is an inhibitor of UGT1A1, and although
Eintrag öffnenKaftrio · 4.5 · CYP2C9 substrates IVA may inhibit CYP2C9; therefore, monitoring of the international normalised ratio (INR) du
Eintrag öffnenKaftrio · 4.5 · CYP2C9 substrates IVA may inhibit CYP2C9; therefore, monitoring of the international normalised ratio (INR) du
Eintrag öffnenKaftrio · 4.5 · CYP3A inducers ELX, TEZ and IVA are substrates of CYP3A (IVA is a sensitive substrate of CYP3A). Concomitant u
Eintrag öffnenKaftrio · 4.5 · CYP3A inducers ELX, TEZ and IVA are substrates of CYP3A (IVA is a sensitive substrate of CYP3A). Concomitant u
Eintrag öffnenKalydeco · 4.5 · 41 CYP2C9 substrates
Eintrag öffnenKalydeco · 4.5 · Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates
Eintrag öffnenKalydeco · 4.5 · Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates
Eintrag öffnenKalydeco · 4.5 · CYP2C9 substrates
Eintrag öffnenKalydeco · 4.5 · CYP3A substrates
Eintrag öffnenKalydeco · 4.5 · CYP3A substrates
Eintrag öffnenKalydeco · 4.5 · Digoxin and other P-gp substrates
Eintrag öffnenKalydeco · 4.5 · Digoxin and other P-gp substrates
Eintrag öffnenKerendia · 4.5 · Effect of 40 mg finerenone on CYP3A4 and CYP2C8 substrates At 40 mg once daily, finerenone is a weak inhibitor
Eintrag öffnenKevzara · 4.5 · Caution should be exercised in patients who start sarilumab treatment while on therapy with CYP3A4 substrates
Eintrag öffnenKevzara · 4.5 · Caution should be exercised in patients who start sarilumab treatment while on therapy with CYP3A4 substrates
Eintrag öffnen